Vanguard Group’s Medicines Co MDCO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-7,632,116
| Closed | -$648M | – | 4143 |
|
|
2019
Q4 | $648M | Buy |
7,632,116
+157,418
| +2% | +$10.5M | 0.02% | 696 |
|
|
2019
Q3 | $374M | Buy |
7,474,698
+35,768
| +0.5% | +$1.43M | 0.01% | 948 |
|
|
2019
Q2 | $271M | Buy |
7,438,930
+460,064
| +7% | +$15M | 0.01% | 1168 |
|
|
2019
Q1 | $195M | Buy |
6,978,866
+119,028
| +2% | +$2.81M | 0.01% | 1361 |
|
|
2018
Q4 | $131M | Buy |
6,859,838
+178,265
| +3% | +$4.15M | 0.01% | 1510 |
|
|
2018
Q3 | $200M | Buy |
6,681,573
+162,702
| +2% | +$6.13M | 0.01% | 1385 |
|
|
2018
Q2 | $239M | Buy |
6,518,871
+239,954
| +4% | +$7.8M | 0.01% | 1228 |
|
|
2018
Q1 | $207M | Buy |
6,278,917
+34,355
| +0.6% | +$1.07M | 0.01% | 1275 |
|
|
2017
Q4 | $171M | Buy |
6,244,562
+153,040
| +3% | +$4.71M | 0.01% | 1405 |
|
|
2017
Q3 | $226M | Buy |
6,091,522
+3,136
| +0.1% | +$116K | 0.01% | 1185 |
|
|
2017
Q2 | $231M | Sell |
6,088,386
-2,344
| -0% | -$104K | 0.01% | 1131 |
|
|
2017
Q1 | $298M | Buy |
6,090,730
+313,876
| +5% | +$14.3M | 0.02% | 959 |
|
|
2016
Q4 | $196M | Buy |
5,776,854
+202,831
| +4% | +$7.19M | 0.01% | 1181 |
|
|
2016
Q3 | $210M | Buy |
5,574,023
+150,632
| +3% | +$5.68M | 0.01% | 1079 |
|
|
2016
Q2 | $182M | Buy |
5,423,391
+202,392
| +4% | +$7.14M | 0.01% | 1105 |
|
|
2016
Q1 | $166M | Buy |
5,220,999
+190,087
| +4% | +$6.21M | 0.01% | 1131 |
|
|
2015
Q4 | $188M | Buy |
5,030,912
+112,703
| +2% | +$4.26M | 0.01% | 1051 |
|
|
2015
Q3 | $187M | Buy |
4,918,209
+140,729
| +3% | +$4.94M | 0.01% | 1030 |
|
|
2015
Q2 | $137M | Buy |
4,777,480
+154,065
| +3% | +$4.29M | 0.01% | 1322 |
|
|
2015
Q1 | $130M | Buy |
4,623,415
+273,429
| +6% | +$7.68M | 0.01% | 1319 |
|
|
2014
Q4 | $120M | Buy |
4,349,986
+56,814
| +1% | +$1.41M | 0.01% | 1285 |
|
|
2014
Q3 | $95.8M | Buy |
4,293,172
+44,320
| +1% | +$1.13M | 0.01% | 1384 |
|
|
2014
Q2 | $123M | Sell |
4,248,852
-58,293
| -1% | -$1.56M | 0.01% | 1252 |
|
|
2014
Q1 | $122M | Buy |
4,307,145
+129,340
| +3% | +$4.28M | 0.01% | 1219 |
|
|
2013
Q4 | $161M | Buy |
4,177,805
+140,278
| +3% | +$5.02M | 0.01% | 1025 |
|
|
2013
Q3 | $135M | Buy |
4,037,527
+382,013
| +10% | +$12.2M | 0.01% | 1051 |
|
|
2013
Q2 | $112M | Buy |
+3,655,514
| New | +$122M | 0.01% | 1094 |
|
Other funds holding MDCO
Vanguard Group's MDCO Position: Q1 2020 in Review
Vanguard Group sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 7,632,116 shares — an estimated $648M sold.
Vanguard Group first reported a position in MDCO in Q2 2013 and held it in 27 quarters. The position peaked at $648M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.
- Vanguard Group reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
- Vanguard Group sold 7,632,116 Medicines Co shares in Q1 2020, an estimated $648M.
- Vanguard Group first reported a position in Medicines Co in Q2 2013 and held it in 27 quarters.
- Vanguard Group's Medicines Co position peaked at $648M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.
Based on Vanguard Group's 13F filing for Q1 2020, filed 15 May 2020.